leisure time -WSS

leisure time

author：leisure time 2025-10-02 17:27:03 - browse：6

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Free speech concerns arise in wake of journal editor Eisen's firing

explore

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

STAT Virtual Event: JPM Recap, Live!

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

American taxpayers paid $1.8 trillion in health care costs in 2022

Nonprofit, backed by Microsoft, to certify AI tools in health care

Senate panel clears PBM, hopsital reforms

focus

leisure time

leisure time

At least 13 dead in Texas as scorching temps continue

Senate panel clears PBM, hopsital reforms

Supreme Court strikes down use of affirmative action

Victims of gun violence feel impacts long after bullet wound

Trump demands the U.S. pay no more for drugs than other countries … again

FDA approves potent Eli Lilly obesity drug, Zepbound

Medical records are filled with copy

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Novavax promises a turnaround & Lilly roils the obesity market

Ambulance rides for just $100? Advisers want major billing fixes

hotspot

Male doctors called my cancer incurable. A female doctor showed it wasn't

FDA early review: GLP

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Hospital chaplains balance Covid safety with patients’ spiritual needs

The new shift in health care is toward less care

leisure time

hotspot

explore

entertainment